One potential explanation is that features like neuroimaging data, APOE genotype, or biomarkers exhibit higher discriminatory power in detecting AD pathology, whereas cognitive impairment alone may not be sufficient to differentiate pathological burden. This evidence concerns the gene APOE and Cognitive impairment.